Octaplex (Protein C Concentrate) - Uses, Dose

Octaplex (Protein C Concentrate derived from human plasma) is indicated in the treatment of purpura fulminant and venous thrombosis secondary to protein C deficiency.

Octaplex (Protein C Concentrate) Uses:

  • Severe congenital protein C deficiency:

    • It is used for the prevention and treatment of venous thrombosis and purpura fulminans in adults as well as pediatric patients with severe congenital protein C deficiency.

Octaplex (Protein C Concentrate) Dose in Adults

  • Patient variables (including age, clinical condition, the severity of protein C deficiency, and plasma levels of protein C) will affect the dosing and duration of therapy.
  • Individualize frequency, duration, and dose based upon protein C activity and patient pharmacokinetic profile.

Octaplex (Protein C Concentrate) Dose in the treatment of severe congenital protein C deficiency:

  • Acute episode/short-term prophylaxis:

    • Initial dose:
      • at 100 to 120 units/kg (for determination of recovery and half-life)
      • Subsequent 3 doses: at 60 to 80 units/kg every 6 hours (adjust to maintain peak protein C activity of 100%)
    • Maintenance dose:
      • at 45 to 60 units/kg every 6 or 12 hours (adjust to maintain recommended maintenance trough protein C activity levels about >25%)
  • Long-term prophylaxis:

    • Maintenance dose:
      • 45 to 60 units/kg every 12 hours (recommended maintenance trough protein C activity levels >25%)

Note:

  • Target peak protein C activity of 100% should be maintained during acute episodes and short-term prophylaxis.
  • After resolution of the acute episode or for long-term prophylaxis, maintain trough levels of protein C activity more than 25%.
  • Higher peak levels of protein C may be required in prophylactic therapy of patients at high risk for thrombosis (eg, infection, trauma, or surgical intervention).
  • If a patient is shifted to an oral anticoagulant, continue protein C replacement until the stable anticoagulation level is obtained.
  • Initiate the oral anticoagulant initially at a low dose and adjust incrementally, rather than using a standard loading dose.

Octaplex (Protein C Concentrate) Dose in Childrens

Note:

  • Patient variables (including age, clinical condition, and plasma levels of protein C) will affect dosing and duration of therapy.
  • Individualize dosing based upon protein C activity and patient's pharmacokinetic profile.

Octaplex (Protein C Concentrate) Dose in the treatment of severe congenital protein C deficiency:

  • Infants, Children, and Adolescents:

    • Acute episode/ short-term prophylaxis:

      • Initial dose:
        • 100-120 units/kg/dose (for determination of recovery and half-life) followed by subsequent 3 doses: at 60-80 units/kg/dose every 6 hours adjusted to maintain peak protein C activity of 100%
      • Maintenance dose:
        • at 45-60 units/kg/dose every 6 or 12 hours titrated to maintain recommended maintenance trough protein C activity levels >25%
    • Long-term prophylaxis:

      • Maintenance dose: at 45-60 units/kg/dose every 12 hours (recommended maintenance trough protein C activity levels >25%)

Note:

  • Target peak protein C activity of 100% should be maintained during acute episodes and short-term prophylaxis.
  • Maintain trough levels of protein C activity >25%.
  • Higher peak levels of protein C may be required in prophylactic therapy of patients at high risk for thrombosis (eg, infection, trauma, surgical intervention).

Purpura fulminans secondary to meningococcemia:

  • Infants >1month, Children, and Adolescents:

    • IV: at 100-150 units/kg/dose every 6 hours for 72 hours then at 50-150 units/kg/dose every 12 hours until target symptom/sign resolution or treatment duration reaches 7 days.

Pregnancy Risk category C

  • Purified human plasma contains Protein C Concentrate.

Protein C use during breastfeeding:

  • Purified human plasma contains Protein C Concentrate.
  • According to the drug manufacturer breastfeeding during treatment should be considered in light of the risks to infants and the benefits to mothers.

Octaplex (Protein C Concentrate) Dose in Kidney disease:

  • There are no dosage adjustments provided in the drug manufacturer's labeling (has not been studied); monitor closely for sodium overload.

Octaplex (Protein C Concentrate) Dose in Liver disease:

  • There are no dosage adjustments provided in the drug manufacturer's labeling.

Side effects of Octaplex (Protein C Concentrate):

  • Hematologic & oncologic:

    • Major hemorrhage
  • Hypersensitivity:

    • Hypersensitivity reaction

Contraindications to Octaplex (Protein C concentrate):

  • The labeling of the drug manufacturer does not list any contraindications.

Warnings and precautions

  • Heparin-induced hemocytopenia (HIT).

    • If there are trace amounts of heparin in the formulation, it may cause HIT. In such cases, an evaluation of platelet count is performed.
  • Hypersensitivity reactions

    • It may contain trace or very little mouse protein and/or Heparin. Discontinue use in the presence of hypersensitivity/allergic reactions.
  • Renal impairment

    • Patients with impaired renal function should be cautious; patients are closely monitored for sodium overload.

Monitoring parameters:

  • Protein C activity (chromogenic assay) before and during therapy;
  • signs and symptoms of bleeding;
  • hemoglobin/hematocrit,
  • PT/INR,
  • platelet count;
  • signs and symptoms of sodium overload in patients with renal disorder.

How to administer Octaplex (Protein C Concentrate)?

IV:

  • Administer by intravenous injection at a rate not to exceed than 2 mL/minute.
  • In infants and children <10 kg, the administration should not exceed a rate of 0.2 mL/kg/minute.
  • The administration must be completed within 3 hours of solution preparation.

Mechanism of action of Octaplex (Protein C Concentrate):

  • Converted to activated proteins C (APC).
  • APC is a serine protease which inactivates factors VIIIa and Va, limiting the formation of thrombotic plaques.
  • In vitro data suggest that inhibition of plasminogen activate inhibitor-1 (PAF-1) may result in profibrinolytic activities, inhibition of macrophages producing tumor necrosis factors, blocking of leukocyte adhesion and limitation of thrombin-induced inflammation.

Notice:

  • There are limited data suggesting that infants and very young kids may have a quicker clearance, lower serum concentration and AUC, greater volume of distribution and a shorter half-life.

The onset of action:

  • 30 minutes

Metabolism:

  • Activated protein C (APC) inactivated by plasma protease inhibitors

Half-life elimination:

  • Median: 9.8 hours;
  • range: 4.9 to 14.7 hours

Time to peak plasma concentrations:

  • 0.5 hours;
  • range: 0.17 to 1.33 hours

International Brands of Protein C concentrate:

  • Ceprotin
  • Octaplex
  • Protexel

Protein C concentrate Brand Names in Pakistan:

No Brands Available in Pakistan.

Recent Posts
La Roche-Posay Anthelios Sunscreen SPF 50: The Ultimate Mineral Face Sunscreen for Daily Use
La Roche-Posay Anthelios Sunscreen SPF 50: The Ultimate Mineral Face Sunscreen for Daily Use
La Roche-Posay Toleriane Double Repair Face Moisturizer with Ceramide & Niacinamide for All Skin Types, Immediate Comfort & Long Lasting Hydration, Fragrance Free
La Roche-Posay Toleriane Double Repair Face Moisturizer with Ceramide & Niacinamide for All Skin Types, Immediate Comfort & Long Lasting Hydration, Fragrance Free
Ultra Strength Gas Relief Softgels, Simethicone 180 mg, Antigas
Ultra Strength Gas Relief Softgels, Simethicone 180 mg, Antigas
Effective Remedies for Constipation
Effective Remedies for Constipation

Comments

NO Comments Found